Chief of the Genitourinary Division for Fox
Chase Cancer Center, and Member of two NCCN Guidelines Panels to
oversee high-impact oncology research journal.
PLYMOUTH MEETING, Pa.,
May 16, 2024 /PRNewswire/ --
Daniel M. Geynisman, MD, is
being announced as the new Editor-in-Chief for JNCCN—Journal of
the National Comprehensive Cancer Network. Dr. Geynisman has a
long history of working with NCCN in a variety of roles and served
as medical oncology section editor for Urologic Oncology:
Seminars and Original Investigations since 2018 and authored
more than 130 peer-reviewed publications. He is an Associate
Professor in the Department of Hematology/Medical Oncology and
Chief of the Division of Genitourinary Medical Oncology at Fox
Chase Cancer Center.
Daniel M.
Geynisman, MD, of Fox Chase Cancer Center, named new
Editor-in-Chief for JNCCN. Learn more at JNCCN.org.
"We are thrilled to welcome Dr. Geynisman into this crucial
position for JNCCN," said Crystal
S. Denlinger, MD, Chief Executive Officer for NCCN. "Our
journal fills many important roles when it comes to oncology
knowledge sharing. In addition to publishing exclusive insights and
updates for the NCCN Guidelines, JNCCN publishes rigorous
health services research, original investigations, and reviews
addressing all aspects of cancer care delivery. Its impact factor
grows every year—currently calculated at 13.4, placing it in the
top 10 percent of cancer-related publications. We look forward to
seeing what new heights we can reach under Dan's leadership."
JNCCN is dedicated to improving the quality of
cancer care locally, nationally, and globally. The journal is
focused on the highest quality original research in the areas of
health services, outcomes, quality improvement, and policy. It is
also a trusted resource for information on the NCCN Clinical
Practice Guidelines in Oncology (NCCN Guidelines®).
"It is an honor to be named Editor-in-Chief for JNCCN,"
said Dr. Geynisman. "Fox Chase Cancer Center was a founding Member
Institution for NCCN, and the opportunity to lead JNCCN is
an enormous privilege. I am excited to expand upon the legacy of
practice setting guidelines and outstanding research contributions
published and look forward to working with the editorial board and
journal staff to continue to build and grow JNCCN as a
premier destination for oncology research."
Dr. Geynisman has a long history of advancing cancer care with
NCCN, including serving as a Member on the NCCN Guidelines Panels
for both Testicular Cancer and Wilms Tumor. He has reviewed
abstracts for presentation at the NCCN Annual Conference, served on
various NCCN grant selection committees, and was himself a past
recipient of NCCN research grants through NCCN's Oncology Research
Program (ORP). He also serves as an ad hoc reviewer for multiple
other journals, including New England Journal of Medicine,
European Urology, Journal of Clinical Oncology, and
Cancer.
Dr. Geynisman is succeeding longtime JNCCN
Editor-in-Chief Margaret Tempero,
MD, UCSF Helen Diller Family Comprehensive Cancer Center, who
now leads the Cancer Early Detection Initiative (CEDI) at UCSF
Helen Diller Family Comprehensive Cancer Center. Under her tenure,
the journal emphasized molecular medicine, health services
research, and principles in cancer care. It has undergone several
redesigns both digitally and in print, including an ongoing shift
towards increased online content with a more streamlined, modern
look. Learn more about her legacy and achievements in the March
issue of JNCCN.
Dr. Geynisman's first issue as Editor-in-Chief will be published
in June 2024. Visit JNCCN.org to
view the newly published May issue, including an official welcome
from the journal's editorial board and staff.
About JNCCN—Journal of the National
Comprehensive Cancer Network
More than 25,000 oncologists and other cancer care professionals
across the United States
read JNCCN—Journal of the National Comprehensive Cancer
Network. This peer-reviewed, indexed medical journal provides
the latest information about innovation in translational medicine,
and scientific studies related to oncology health services
research, including quality care and value, bioethics, comparative
and cost effectiveness, public policy, and interventional research
on supportive care and
survivorship. JNCCN features updates on the NCCN
Clinical Practice Guidelines in Oncology (NCCN
Guidelines®), review articles elaborating on guidelines
recommendations, health services research, and case reports
highlighting molecular insights in patient
care. JNCCN is published by
Harborside/BroadcastMed. Visit JNCCN.org. To inquire if you
are eligible for a FREE subscription
to JNCCN, visit NCCN.org/jnccn/subscribe. Follow
JNCCN at x.com/JNCCN.
About the National Comprehensive Cancer Network
The
National Comprehensive Cancer Network®
(NCCN®) is a not-for-profit alliance of
leading cancer centers devoted to patient care, research, and
education. NCCN is dedicated to improving and facilitating quality,
effective, equitable, and accessible cancer care so all patients
can live better lives. The NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines®) provide
transparent, evidence-based, expert consensus recommendations for
cancer treatment, prevention, and supportive services; they are the
recognized standard for clinical direction and policy in cancer
management and the most thorough and frequently-updated clinical
practice guidelines available in any area of medicine. The NCCN
Guidelines for Patients® provide expert cancer
treatment information to inform and empower patients and
caregivers, through support from the NCCN
Foundation®. NCCN also advances continuing
education, global initiatives, policy, and research collaboration
and publication in oncology. Visit NCCN.org for more
information.
Media Contact:
Rachel
Darwin
267-622-6624
darwin@nccn.org
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dr-daniel-geynisman-named-new-editor-in-chief-for-jnccnjournal-of-the-national-comprehensive-cancer-network-302147761.html
SOURCE National Comprehensive Cancer Network